FDA Finalizes FAQ Guide for Cell, Gene Therapies

FDA's Center for Biologics Evaluation and Research has finalized its frequently-asked-questions guidance for developers of cellular and gene therapy products, closing out a draft first issued in November 2024. The final guidance, announced in the Federal Register on 20 August, keeps the draft's structure and most of its content largely intact — FDA says the changes are mostly editorial, plus added resource links and typo fixes. The one substantive addition: new language on limiting animal use in nonclinical studies, a topic the draft did not address.

A reference document, not a new policy

The FAQ format is deliberate. Rather than setting out a single recommended approach the way a topic-specific guidance would, the document collects the questions CBER's review staff say they hear most often from cell and gene therapy (CGT) sponsors and answers them directly — the kind of thing that used to circulate informally between sponsors and their regulatory consultants. It spans the full arc of development: how a pre-IND meeting differs from the newer INTERACT meeting pathway, what belongs in a chemistry, manufacturing, and controls (CMC) package at different stages, how to select an appropriate animal species for a nonclinical study, and what clinical and clinical-pharmacology data reviewers expect to see.

What's new: animal-use language

The one addition FDA calls out as substantive is a new answer addressing New Approach Methodologies, or NAMs — non-animal or reduced-animal testing approaches such as in vitro models, organ-on-a-chip systems, and computational modeling. FDA states in the final guidance that it supports the use of NAMs and the 3Rs principles — reduce, refine, and replace animal use — to encourage judicious use of animals in nonclinical development programs. That language did not appear in the November 2024 draft; its addition tracks a broader push across FDA's centers, including CDER's own initiatives, to build alternatives to traditional animal testing into nonclinical review expectations rather than treating them as a future aspiration.

The long-term safety monitoring holds

One of the more operationally demanding recommendations carries over unchanged from the draft: sponsors should plan for both short- and long-term safety monitoring of trial participants, tracking some products' recipients for delayed adverse events for as long as 15 years after exposure. For a gene therapy using an integrating vector or a genome-editing approach, that is not a paperwork exercise — it means designing a follow-up infrastructure, informed-consent process, and data-retention plan at the outset of a program that may not read out final safety data until long after the sponsor's own commercial timeline has moved on. The guidance also confirms that commercial INDs must be submitted in eCTD format through FDA's Electronic Submission Gateway, while noncommercial, investigator-initiated INDs have the option but not the obligation to use eCTD.

Why this belongs on a CGT team's reading list

An FAQ guidance is easy to skim past because it reads like a reference document rather than a rule change, but that is exactly what makes it worth a close read: it is where CBER writes down the answers reviewers have been giving informally, which means it previews what a review division will expect a sponsor to already know. For teams building a nonclinical program now, the NAMs language is a signal worth raising with toxicology leads before study design locks in — not because it mandates anything, but because it tells sponsors which arguments a reviewer will find persuasive when a species-selection or animal-use question comes up in a pre-IND meeting.